Advancing Therapeutic IgE – Collaborative Discovery of MOv18's Mechanism in Ovarian Cancer
April 10, 2025
SUMMARY:
Ovarian cancer is the most lethal gynecological malignancy, with limited treatment options and a profoundly immunosuppressive tumor microenvironment (TME). Tumor-associated macrophages(TAMs) are abundant in ovarian tumors and ascites, where they play a major role in suppressing anti-tumor T cell responses.
In this collaborative study with King’s College London, researchers explored a first-in-class IgE
monoclonal antibody (mAb), MOv18 IgE, targeting Folate Receptor-α (FRα), and investigated how it reshapes macrophage behavior and T cell interactions, using Seromyx's profiling tools to uncover previously uncharacterized Fc effector mechanisms.
IN COLLABORATION WITH:
King's College London - Karagiannis Lab
Authors: Stefanutti E, Ramani R, Whitener B, Dang H, Bélanger S, Somasundaram L, Cortina K, De Marco A, Tam T, Chai Q, Cameroni E, Gupta R, Schmid MA, Miller JL, Zumsteg AB, Purcell LA, Drewry LL. 0. Analysis of Fc-dependent effector functions of anti-malaria circumsporozoite protein antibodies. Microbiol Spectr 0:e00863-25. Journal: Microbiology Spectrum
Antibody Engineering & Therapeutics 2025
The World Vaccine Congress Europe 2025
Festival of Biologics
The Fc-Mediated Effector Function Summit
Authors: Kaplonek P, et al. Sci Transl Med. 2022 May 18;14(645):eabm2311.
Authors: Hawman, David W. et al. eBioMedicine, Volume 115, 105698
Authors: Crescioli, S, Jatiani, S, & Moise, L, (2025). mAbs, 17(1). Journal: mAbs
Authors: Osborn, G., López-Abente, J., Adams, R. et al.
Woburn, MA / Newark, DE – October 1st, 2024 - SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, a leading provider for life science solutions and tools, are excited to announce the release of their joint study on the...
